NCT06762808 2025-08-15
Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
15 trialsNCT06416436 2025-06-29
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
University of Kansas Medical Center
Phase 1 Withdrawn
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT05935774 2023-08-25
OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
University of Washington
Phase 2 Withdrawn
NCT05510427 2023-08-15
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04249167 2023-01-06
Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
Mayo Clinic
Phase EARLY_PHASE1 Withdrawn
NCT05327738 2022-12-14
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT04630210 2022-06-15
AteBrO
Universitaire Ziekenhuizen KU Leuven
Phase EARLY_PHASE1 Withdrawn
NCT05007769 2021-11-05
RAN
Washington University School of Medicine
Phase 2 Withdrawn
NCT04020094 2021-09-22
AtezoVax
University of Utah
Phase 2 Withdrawn
NCT03786419 2021-05-13
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
Health Pharma Professional Research
Phase 2 Withdrawn
NCT04272645 2020-07-15
Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT03498222 2020-02-25
iTRAP
Queen Mary University of London
Phase 1 Withdrawn
NCT03340558 2018-10-09
ATELIER
Duke University
Phase 2 Withdrawn
NCT02495636 2017-06-22
Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Yale University
Phase 2 Withdrawn